Literature DB >> 2035135

Surgical and chemotherapeutic treatment of hepatic metastases from carcinoma of the breast.

D Elias1, P Lasser, M Spielmann, F May-Levin, O el Malt, H Thomas, H Mouriesse.   

Abstract

To date, no five year survival rates have been reported for patients with hepatic metastases (HM) from breast origin treated by chemotherapy or hormone therapy. This study was done to evaluate whether or not surgical excision of such metastatic disease associated with chemotherapy has any effect on such a poor prognosis. Between May 1985 and September 1988, 22 patients with a diagnosis of isolated (solitary or multiple) HM have been surgically treated. The therapeutic approach also included systemic preoperative and postoperative chemotherapy. Laparotomy findings for those 22 patients are presented. There were benign hepatic lesions in four patients (four different histologic types) and hepatectomy was done in two patients. Diffuse metastatic disease contraindicated any attempt at hepatic resection in six patients. Hepatectomy was possible in 12 patients. There was no postoperative mortality and minimal morbidity. One-half of the patients with metastases had one or more positive lymph nodes at the hepatic pedicule. Median survival time for 12 patients treated by hepatectomy was 37 +/- 9 months after hepatectomy and 42 +/- 3 months after the discovery of HM. Eleven patients had other metastases after an average period of 11.8 months after hepatectomy, and the liver was the first site of recurrence in eight. One patient underwent a hepatectomy twice. Two patients were free of disease 29 to 46 months postoperatively in spite of poor prognostic features on the excised specimen. Although the median survival time was two times better than with usual treatment, we believe this procedure is of doubtful benefit. In this situation, hepatectomy acts as cytoreductive surgical treatment, with the main limiting factor being the relatively low effectiveness of chemotherapy. This type of therapy can be applied only to a restricted number of patients, and if we decide to proceed with this study, we will have to modify the protocol of chemotherapy radically.

Entities:  

Mesh:

Year:  1991        PMID: 2035135

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  12 in total

1.  The role of liver-directed surgery in patients with hepatic metastasis from primary breast cancer: a multi-institutional analysis.

Authors:  Georgios A Margonis; Stefan Buettner; Kazunari Sasaki; Yuhree Kim; Francesca Ratti; Nadia Russolillo; Alessandro Ferrero; Nickolas Berger; T Clark Gamblin; George Poultsides; Thuy Tran; Lauren M Postlewait; Shishir Maithel; Alex D Michaels; Todd W Bauer; Hugo Marques; Eduardo Barroso; Luca Aldrighetti; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2016-06-29       Impact factor: 3.647

2.  Radiofrequency ablation as a treatment strategy for liver metastases from breast cancer.

Authors:  Anne M Covey; Constantinos T Sofocleous
Journal:  Semin Intervent Radiol       Date:  2008-12       Impact factor: 1.513

3.  Percutaneous transhepatic portal vein embolization: rationale, technique, and outcomes.

Authors:  Rony Avritscher; Thierry de Baere; Ravi Murthy; Frederic Deschamps; David C Madoff
Journal:  Semin Intervent Radiol       Date:  2008-06       Impact factor: 1.513

4.  Treatment outcome of patients with liver-only metastases from breast cancer after mastectomy: a retrospective analysis.

Authors:  Xiao Feng Duan; Na Na Dong; Ti Zhang; Qiang Li
Journal:  J Cancer Res Clin Oncol       Date:  2011-07-26       Impact factor: 4.553

5.  Aggressive treatment for hepatic metastases from breast cancer: results from a single center.

Authors:  F Polistina; G Costantin; A Febbraro; E Robusto; G Ambrosino
Journal:  World J Surg       Date:  2013-06       Impact factor: 3.352

6.  Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation--intermediate and long-term survival rates.

Authors:  Maria Franca Meloni; Anita Andreano; Paul F Laeseke; Tito Livraghi; Sandro Sironi; Fred T Lee
Journal:  Radiology       Date:  2009-08-25       Impact factor: 11.105

7.  Liver resection for breast cancer metastasis: does it improve survival?

Authors:  Jean Lubrano; Horace Roman; Sophie Tarrab; Benoit Resch; Loïc Marpeau; Michel Scotté
Journal:  Surg Today       Date:  2008-03-27       Impact factor: 2.549

8.  Surgery for liver metastases from breast cancer.

Authors:  Dominique Elias; Daniela Di Pietroantonio
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

Review 9.  Renewed considerations on the utility (or the futility) of hepatic resections for breast cancer liver metastases.

Authors:  Gian Luca Grazi
Journal:  Hepatobiliary Surg Nutr       Date:  2021-01       Impact factor: 8.265

10.  Prognostic factors related to surgical outcome of liver metastases of breast cancer.

Authors:  Daniel V Kostov; Georgi L Kobakov; Daniel V Yankov
Journal:  J Breast Cancer       Date:  2013-06-28       Impact factor: 3.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.